Brentuximab vedotin (solution)

Name: Brentuximab vedotin (solution)
Brand: MedChemExpress
SKU: HY-P99107A
Rating: 4.5 (1 reviews)

Cat. No.: HY-P99107A Purity: 99.73%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Brentuximab vedotin (solution) (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). The antibody portion is Brentuximab (HY-P99151), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Brentuximab vedotin (solution) inhibits CD30-positive cells with an IC₅₀ of 2.5 ng/mL. Brentuximab vedotin (solution) can be used for the research of relapsed and refractory Hodgkin lymphoma.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Brentuximab vedotin (solution) 화학구조

CAS No. : 914088-09-8

사이즈	재고	수량
1 mg	해외재고보유	Estimated Time of Arrival: December 31
5 mg	해외재고보유	Estimated Time of Arrival: December 31
10 mg	견적 받기
50 mg	견적 받기

or 대량구매 문의

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

고객리뷰

Based on 1 publication(s) in Google Scholar

1 Publications Citing Use of MCE Brentuximab vedotin (solution)

•Adv Sci (Weinh). 2026 Feb 28:e17353.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
순도&문서
References
고객리뷰

제품 설명

In Vitro

Brentuximab vedotin (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). Brentuximab vedotin inhibits CD30-positive cells with an IC₅₀ of 2.5 ng/mL. Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma^[1]^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

분자량

153000 (average)

CAS No.

914088-09-8

Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Brentuximab vedotin (solution)]

선적

Shipping with dry ice.

보관

-80°C, protect from light

순도&문서

Purity: 99.73%

Select Batch:

Data Sheet (265 KB) SDS (251 KB)

COA (232 KB) Others (193 KB) SEC-HPLC (185 KB)

Handling Instructions (2659 KB)

References

[1]. Shea L, Mehta-Shah N. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma. Curr Hematol Malig Rep. 2020 Feb;15(1):9-19. [Content Brief]

[2]. Francisco JA, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003 Aug 15;102(4):1458-65. [Content Brief]